Week 0 | Week 16 | Week 32 | ||
---|---|---|---|---|
Control group (N=60) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | F2,118 (p value) |
ASES (score range; higher score=greater self-efficacy) | ||||
ASES-Pain (5–50) | 25.3 (22.4 to 28.2) | 26.5 (23.9 to 29.2) | 27.5 (24.6 to 30.3) | 2.03 (0.135)† |
ASES-Other symptoms (6–60) | 34.2 (30.9 to 37.4) | 35.0 (31.4 to 38.6) | 35.3 (31.5 to 39.0) | 0.40 (0.673)† |
AIMS2-SF (score range; zero=good health status) | ||||
AIMS2: physical (0–10) | 3.1 (2.4 to 3.8) | 3.0 (2.4 to 3.6) | 3.0 (2.4 to 3.7) | 0.09 (0.917) |
AIMS2: symptoms (0–10) | 5.0 (4.2 to 5.8) | 4.6 (3.8 to 5.4) | 5.1 (4.2 to 6.0) | 2.34 (0.101) |
AIMS2: affect(0–10) | 3.7 (3.2 to 4.3) | 3.8 (3.3 to 4.2) | 4.1 (3.5 to 4.7) | 2.18 (0.117) |
AIMS2: social(0–10) | 5.5 (5.1 to 6.0) | 5.6 (5.1 to 6.0) | 5.7 (5.3 to 6.2) | 1.86 (0.160) |
AIMS2: work‡(0–10) | 2.0 (0.9 to 3.1) | 3.4 (1.9 to 4.8) | 2.4 (−0.01 to 4.8) | 3.84 (0.028) |
PKQ (score range, higher score=higher level of knowledge) | ||||
Total PKQ (0–12) | 8.6 (7.9 to 9.2) | 8.7 (8.1 to 9.3) | 9.1 (8.4 to 9.8) | 1.96 (0.146) |
Intervention group (N=68) | Mean (95% CI) | Mean (95% CI) | Mean (95% CI) | F2,134 (p value) |
ASES(score range; higher score=greater self-efficacy) | ||||
ASES-Pain (5–50) | 23.4 (21.2 to 25.6) | 27.0 (24.6 to 29.4) | 30.7 (28.2 to 33.2) | 37.5 (<0.001)† |
ASES-Other symptoms (6–60) | 30.6 (27.8 to 33.4) | 34.5 (31.4 to 37.5) | 38.7 (35.7 to 41.7) | 37.2 (<0.001)† |
AIMS2-SF (score range; zero=good health status) | ||||
AIMS2: physical (0–10) | 3.1 (2.6 to 3.6) | 2.8 (2.3 to 3.3) | 2.8 (2.3 to 3.4) | 2.35 (0.099) |
AIMS2: symptoms (0–10) | 5.4 (4.8 to 6.1) | 4.7 (4.0 to 5.4) | 4.3 (3.7 to 5.0) | 11.8 (<0.001) |
AIMS2: affect (0–10) | 4.3 (3.8 to 4.8) | 4.1 (3.5 to 4.6) | 3.6 (3.1 to 4.1) | 12.0 (<0.001) |
AIMS2: social (0–10) | 5.6 (5.2 to 6.0) | 5.5 (5.0 to 6.0) | 5.7 (5.2 to 6.2) | 1.35 (0.263) |
AIMS2: work‡(0–10) | 2.3 (1.2 to 3.4) | 2.8 (1.6 to 3.9) | 2.8 (1.5 to 5.0) | 0.60 (0.552) |
PKQ (score range, higher score=higher level of knowledge) | ||||
Total PKQ (0–12) | 8.6 (8.0 to 9.1) | 9.0 (8.5 to 9.5) | 9.2 (8.7 to 9.8) | 5.22 (0.007) |
*Analysis not adjusted for baseline values as examining changes over time including values at baseline.
†Bonferroni-adjusted p value=0.025 for significance at the α level.
‡All missing data imputed except for AIMS2-SF: Work where scores are only available for the patients who were working, week 16 and week 32 control group N=26 and intervention group N=33.
ASES, Arthritis Self Efficacy Scale; PKQ, patient knowledge questionnaire.